AustinPx and Microsize: A Partnership to Accelerate KinetiSol Technology

• AustinPx, a contract development and manufacturing organisation (CDMO), has announced a strategic partnership with Microsize.

• The collaboration aims to accelerate the commercial application of AustinPx’s KinetiSol™ Technology platform.

• The KinetiSol™ Technology is projected to be available at Microsize for Good Manufacturing Practice (GMP) production by the end of 2024.

AustinPx, a CDMO specialising in bioavailability enhancement of orally delivered small molecule drug candidates, and Microsize, a leading active pharmaceutical ingredient enhancement CDMO, announced a strategic partnership on January 31, 2024. The partnership aims to accelerate the commercial application of AustinPx’s KinetiSol™ Technology platform.

The collaboration will enable AustinPx’s clients to manufacture their late-phase clinical and commercial KinetiSol drug product intermediate at Microsize’s purpose-built, FDA-inspected facility. KinetiSol is an innovative technology that utilizes frictional and shear energies to generate amorphous solid dispersions (ASD) in seconds, without the use of solvents.

Elizabeth Hickman, chief business officer of AustinPx, expressed her excitement about the partnership, stating, “AustinPx is excited to partner with Microsize, a like-minded client-centric CDMO, on the commercial enablement of our KinetiSol Technology.

As part of the agreement, AustinPx will transfer its proprietary KinetiSol equipment, software, and know-how to Microsize’s Quakertown facility. In turn, Microsize will install and qualify the equipment for late-phase and commercial manufacturing within their cGMP manufacturing plant.

The KinetiSol Technology is projected to be available at Microsize for GMP production by the end of 2024. TJ Higley, chief executive officer of Microsize, expressed his pleasure about onboarding such a powerful technology that has been shown to outperform alternative ASD technologies.